Kains J P, Hardy J C, Chevalier C, Collier A
Department of Internal Medicine, Université Libre de Bruxelles.
Acta Clin Belg. 1990;45(5):306-10. doi: 10.1080/17843286.1990.11718104.
Retroperitoneal fibrosis has been observed in two patients with Parkinson's disease treated with bromocriptine. The patients complained of abdominal or lower back pain and presented with various degrees of renal insufficiency, with anuria in one. Laboratory evaluation furthermore showed an increased sedimentation rate and inflammatory anemia. Computerized tomography disclosed marked retroperitoneal thickening, and biopsy was performed in one patient. The symptoms appeared eighteen months and five years after treatment was started, at doses of 20 and 22.5 mg of bromocriptine daily. The medication was discontinued in both patients and steroid therapy was initiated, with resolution of all clinical, biological and radiological evidence of disease. This potential but rare complication of a widely prescribed drug warrants monitoring of renal function and sedimentation rate in patients undergoing bromocriptine treatment.
在两名接受溴隐亭治疗的帕金森病患者中观察到腹膜后纤维化。患者主诉腹部或下背部疼痛，并出现不同程度的肾功能不全，其中一名患者无尿。实验室检查还显示血沉加快和炎症性贫血。计算机断层扫描显示腹膜后明显增厚，对一名患者进行了活检。症状分别在开始治疗18个月和5年后出现，每日溴隐亭剂量分别为20毫克和22.5毫克。两名患者均停用该药物并开始使用类固醇治疗，所有疾病的临床、生物学和放射学证据均消失。这种广泛使用的药物潜在但罕见的并发症，需要对接受溴隐亭治疗的患者监测肾功能和血沉。
